Scleroderma
Proposed Treatments in Scleroderma
Herbs and Supplements to Avoid in Scleroderma
References
1 Zarafonetis CJ, Dabich L, Skovronski JJ, et al. Retrospective studies in scleroderma: skin response to potassium para-aminobenzoate therapy. Clin Exp Rheumatol. 1988;6:261–268.
2 Zarafonetis CJ, Dabich L, Negri D, et al. Retrospective studies in scleroderma: effect of potassium para-aminobenzoate on survival. J Clin Epidemiol. 1988;41:193–205.
3 Clegg DO, Reading JC, Mayes MD. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. J Rheumatol. 1994;21:105–110.
4 Kartnig T. Clinical applications of Centella asiatica (L.) Urb. Herbs Spices Med Plants. 1988;3:145–173.
5 Mavrikakis ME, Lekakis JP, Papamichael CM, et al. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis. Int J Vitam Nutr Res . 2003;73:3–7.
6 Maeda M, Kachi H, Ichihashi N, et al. The effect of electrical acupuncture-stimulation therapy using thermography and plasma endothelin (ET-1) levels in patients with progressive system sclerosis (PSS). J Dermatol Sci. 1998;17:151–155.
7 Sternberg EM, Van Woert MH, Young SN, et al. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med. 1980;303:782–787.
8 Joly P, Lampert A, Thomine E, et al. Develoment of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. J Am Acad Dermatol. 1991;25:332–333.
9 Auffranc JC, Berbis P, Fabre JF, et al. Sclerodermiform and poikilodermal syndrome observed during treatment with carbidopa and 5-hydroxytryptophan [translated from French]. Ann Dermatol Venereol. 1985;112:691–692.
Revision Information
- Reviewer: EBSCO CAM Review Board
- Review Date: 07/2012 -
- Update Date: 07/25/2012 -

